Showing posts with label Billing. Show all posts
Showing posts with label Billing. Show all posts

Saturday, December 22, 2012

Unstoppable Fraud Machines II: Compounding and Repackaging posted on 04/22/2010

By Eugene Keefe
Keefe, Campbell Associates

One of our national clients advised of a recent trenddrug compounding and repackaging to make the simple pharmaceutical process much more expensive. In follow-up to our first article, we note in recent years, compound drugs and drug repackaging have gone hand-in-glove as ways in which workers compensation claims handlers often have no idea what they are paying in handling Illinois workers compensation claims. As we have advised on numerous occasions, it is amazing Illinois has a medical fee schedule without a prescription fee schedule. This change wont happen until Illinois business demands it.

Compounded drugs are hand-made rather than mass-produced, and supposedly tailored to the needs of individual patients. These practices are mainly regulated by the states instead of the federal Food and Drug Administration. The disparities resulting from 50 sets of rules and levels of technical and inspection prowess shouldnt be allowed to continue. Repackaged drugs are prescription or over-the-counter drugs taken from initial drug producers and repackaged and repriced, usually by physician/clinic dispensers. The cost is from two times higher to twelve times higher. In one study, repackaged drugs accounted for less than a third of all prescriptions but over half of all dollars paid. The concept is especially troubling when one considers the overwhelming majority of the top 20 drugs are generic.

As has been the case for the last several years, the average prescription cost of compound drugs is well over the national average. A growing percentage of the providers dispensing compound drugs submit via paper, and many payers have had limited capabilities with adjudicating these bills at the appropriate or allowable rates. While the number of the compound drug paper bills is currently a small percentage of most national payers overall prescription volume, the dollars associated with these transactions and the potential savings can be high.

Continue reading here

Saturday, August 18, 2012

Correct coding of compound drugs for BCBST in Tennessee


Any legend drug altered from its manufactured form for use by a specific
patient is considered a compound. Since compounded medications do not have an
NDC number, specific HCPCS Level II codes may not be used. Eligible compound
drugs must be billed with the most appropriate HCPCS Level II unclassified/not otherwise classified code. An example of a compounded medication is bevacizumab (Avastin®) for intravitreal
injection.  Bevacizumab is supplied from   the manufacturer in 400 mg and 100 mg
vials with a concentration of 25 mg / mL. It is typically repackaged into single dose
syringes with a concentration of 1.25 mg /0.05 mL for intravitreal injection and must
be prepared under sterile conditions by a compounding pharmacy prior to ocular use.
Effective Aug. 1, 2012, for each date of service compound drugs are administered,
instilled, inserted, or implanted, a reasonable compounding fee will be
reimbursed for commercial and BlueAdvantage claims if the pharmacy
compounding fee is submitted on a separate line item billed with the appropriate HCPCS
code for Pharmacy compounding and dispensing services.  Billing guidelines for compound drugs can be reviewed in the billing and reimbursement section of the BlueCross
BlueShield of Tennessee Provider Administration Manual found online at
www.bcbst.com.

Article is found here.